Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Her-2 Negative Breast Cancer|HRR Gene Mutation
Interventions: DRUG: Camrelizumab|DRUG: Fluzoparib|DRUG: Nab-paclitaxel
Sponsor: Ying Lin